



JAMES PHILLIPS, MRCGP ^{2*}, DAVID RUSSELL JONES, FRCP ^{1*}, JOHN WRIGHT, FCRP ¹, ANNA BRACKENRIDGE, MRCP ¹, ROGER NEW, PhD ² and GURPAL BANSAL, BSc ². ¹ Royal Surrey County Hospital, Guildford, SY, United Kingdom and ² Diabetology Ltd, St Helier, Jersey,, United Kingdom

1)



Background Aims: Oral insulin delivery is being developed as an alternative to subcutaneous (and other) delivery forms of Insulin, and may offer a closer match to normal physiological insulin release. In an ongoing open study using healthy volunteers, a novel oral insulin formulation (DTY001), based on transmembrane transport, was administered the effects monitored via plasma insulin and c-peptide levels, along with blood glucose measurements.

Materials Methods: The arm of the study reported here used 3 healthy volunteers, fasted overnight, who had a fine bore naso-jejunal feeding tube inserted. Each subject was then administered 170iu Insulin in the oral formulation, via the Naso-jejunal tube. IV Access for test sampling, and dextrose infusion (if required) was previously established.

2)




3)



4)

In a follow-on arm to this study 2 subjects were given 340iu of Insulin by the same method with the following Glucose & Plasma Insulin Responses:



Author for Correspondence: James N Phillips, MB ChB MRCGP
 Department/Institution: Diabetology Ltd
 Address: No 1 Les Dents Blanches, Jardy
 City/State/Zip/Country: Châtel, Haut-Savoie, 74390, France
 Phone: +33450735260 Fax: +33 450734750 E-mail: jp@diabetology.co.uk